# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Chronic Myeloproliferative Disorders

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 340 results.
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Status: Recruiting
Last Changed: Oct 22, 2020
First Received: Aug 01, 2019
Disease(s): Myeloproliferative Neoplasm
Intervention(s): Navitoclax, Ruxolitinib, Celecoxib
Locations: UCLA /Id# 222784, Los Angeles, California, United States
Yale University /ID# 224393, New Haven, Connecticut, United States
Northwestern University Feinberg School of Medicine /ID# 224203, Chicago, Illinois, United States
Texas Tech University Health Sciences Center (TTUHSC) - El Paso /ID# 223920, El Paso, Texas, United States
IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 224071, Meldola, Emilia-Romagna, Italy
... and 9 other locations.
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Status: Not yet recruiting
Last Changed: Mar 18, 2020
First Received: Mar 18, 2020
Disease(s): Myeloproliferative Neoplasm
Intervention(s): BCR-ABL gene PCR
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
Status: Recruiting
Last Changed: Apr 09, 2020
First Received: Apr 09, 2020
Disease(s): Myeloproliferative Neoplasms
Intervention(s): TQ05105
Locations: West China Hospital ,Sichuan University, Chendu, Sichuan, China
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: Dec 10, 2019
Disease(s): Myeloproliferative Neoplasm
Intervention(s): DOACs
Locations: Mount Sinai New York, New York, New York, United States
Princess Margaret Cancer Centre Toronto, Toronto, Canada
Centre Hospitalier Universitaire de Brest, Brest, France
RWTH Aachen University, Aachen, Germany
Johannes Wesling Klinikum Minden, Minden, Germany
... and 14 other locations.
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
Status: Not yet recruiting
Last Changed: May 07, 2020
First Received: May 07, 2020
Disease(s): Myeloproliferative Neoplasm
Intervention(s): Questionnaire
Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms
Status: Recruiting
Last Changed: Jun 19, 2020
First Received: Nov 26, 2019
Disease(s): Myeloproliferative Neoplasm
Intervention(s): 2 additional tubes of blood
Locations: CHU Angers, Angers, France
CH Annecy Genevois, Annecy, France
CH Avignon, Avignon, France
CHU Bordeaux, Hématologie Biologique, Bordeaux, France
CHU Bordeaux, Hématologie Clinique et Thérapie Cellulaire, Bordeaux, France
... and 19 other locations.
Myeloproliferative Neoplasms (MPN) and COVID-19
Status: Recruiting
Last Changed: Jul 23, 2020
First Received: May 12, 2020
Disease(s): Myeloproliferative Neoplasm, COVID
Locations: New York-Presbyterian/Weill Cornell Medical Center, New York, New York, United States
Hopital Saint-Louis, Paris, France
University Medical Center RWTH, Aachen, Germany
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center, Minden, Germany
Ospedale San Gerardo di Monza, Monza, Monza Brianza, Italy
... and 36 other locations.
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Status: Not yet recruiting
Last Changed: Nov 16, 2020
First Received: Nov 16, 2020
Disease(s): Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Intervention(s): Captopril
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
Status: Recruiting
Last Changed: Mar 19, 2020
First Received: Jun 15, 2018
Disease(s): Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder
Intervention(s): Ruxolitinib
Locations: Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Seoul National University Hospital, Seoul, Korea, Republic of
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Status: Not yet recruiting
Last Changed: Sep 24, 2020
First Received: Feb 24, 2020
Disease(s): Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
Intervention(s): Ruxolitinib, Enasidenib
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
... and 7 other locations.